However, the company reported an 8 percent decrease in net income to $18.3 million. The company’s president and CEO Brian Concannon said the company is still recovering from the OrthoPAT recall and continues to resolve its quality issues. The company’s plasma and blood management solutions business lines experienced growth during this period.
Related Articles on Orthopedic Devices:
NuVasive Shares Rise After Judge’s Ruling
Zimmer’s 2.9% Sales Increase Driven by Foreign Markets
Interventional Spine Receives FDA Clearance for Spine Device
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
